4503.T Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 09:15):

Stats
Объем за сегодня	13.56M
Средний объем	9.16M
Рыночная капитализация	2 700.41B
EPS	¥0 ( 2024-04-25 )
Last Dividend	¥30.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	555.72
ATR14	¥1.046 (0.07%)

Объем Корреляция

Длинно: 0.14 (neutral)

Кратко: 0.78 (moderate)

Signal:(69.956) Neutral

Astellas Pharma Inc. Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Astellas Pharma Inc. Корреляция - Валюта/Сырье

0.35
( neutral )

0.28
( neutral )

-0.14
( neutral )

-0.38
( neutral )

-0.20
( neutral )

-0.34
( neutral )

Astellas Pharma Inc. Финансовые показатели

Annual	2023
Выручка:	¥1 603.67B
Валовая прибыль:	¥1 212.37B (75.60 %)
EPS:	¥9.50

FY	2023
Выручка:	¥1 603.67B
Валовая прибыль:	¥1 212.37B (75.60 %)
EPS:	¥9.50

FY	2022
Выручка:	¥1 518.62B
Валовая прибыль:	¥1 230.27B (81.01 %)
EPS:	¥54.24

FY	2022
Выручка:	¥1 296.16B
Валовая прибыль:	¥1 043.15B (80.48 %)
EPS:	¥67.08

Financial Reports:

No articles found.

Astellas Pharma Inc. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥30.00 (N/A)	¥0 (N/A)	¥30.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Astellas Pharma Inc. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 8.06 - good (80.57%) | Divividend Growth Potential Score: 4.81 - Stable (3.74%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥3.00	2000-03-28
Last Dividend	¥30.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	48	--
Total Paid Out	¥591.00	--
Avg. Dividend % Per Year	0.00%	--
Score	3.41	--
Div. Sustainability Score	8.06
Div.Growth Potential Score	4.81
Div. Directional Score	6.43	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

3.41

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
9010.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
8584.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7908.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
7065.T	Ex Dividend Junior	2023-08-30	Annually	0.00%
6373.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
5301.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
4350.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3526.T	Ex Dividend Junior	2024-03-28	Sporadic	0.00%
2753.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
9639.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.00805	1.500	9.84	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00362	1.200	9.88	10.00	[0 - 0.3]
returnOnEquityTTM	0.00817	1.500	-1.020	-1.530	[0.1 - 1]
payoutRatioTTM	9.04	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	0.929	0.800	-0.354	-0.283	[1 - 3]
quickRatioTTM	0.687	0.800	-0.663	-0.530	[0.8 - 2.5]
cashRatioTTM	0.261	1.500	9.66	10.00	[0.2 - 2]
debtRatioTTM	0.258	-1.500	5.70	-8.56	[0 - 0.6]
interestCoverageTTM	8.97	1.000	7.79	7.79	[3 - 30]
operatingCashFlowPerShareTTM	97.61	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	51.61	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.576	-1.500	7.69	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.797	1.000	0.0457	0.0457	[0.2 - 0.8]
operatingProfitMarginTTM	0.0672	1.000	-0.657	-0.657	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.190	1.000	-0.0541	-0.0541	[0.2 - 2]
assetTurnoverTTM	0.449	0.800	-0.338	-0.271	[0.5 - 2]
Total Score				8.06

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	209.28	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.00817	2.50	-0.656	-1.530	[0.1 - 1.5]
freeCashFlowPerShareTTM	51.61	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	4.65	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	97.61	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	9.04	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	-10.93	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.109	1.000	9.77	0	[0.1 - 0.5]
Total Score				4.81

Astellas Pharma Inc.

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.